1-12 of 12
Alvin F. Wong
Close
Sort by
Journal Articles

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Clinical Trials & Observations
David S. Siegel, Thomas Martin, Michael Wang, Ravi Vij, Andrzej J. Jakubowiak, Sagar Lonial, Suzanne Trudel, Vishal Kukreti, Nizar Bahlis, Melissa Alsina, Asher Chanan-Khan, Francis Buadi, Frederic J. Reu, George Somlo, Jeffrey Zonder, Kevin Song, A. Keith Stewart, Edward Stadtmauer, Lori Kunkel, Sandra Wear, Alvin F. Wong, Robert Z. Orlowski, Sundar Jagannath
Journal: Blood
Blood (2012) 120 (14): 2817–2825.
https://doi.org/10.1182/blood-2012-05-425934
Published: 2012
Includes: Supplemental data
Journal Articles

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Clinical Trials & Observations
Ravi Vij, Michael Wang, Jonathan L. Kaufman, Sagar Lonial, Andrzej J. Jakubowiak, A. Keith Stewart, Vishal Kukreti, Sundar Jagannath, Kevin T. McDonagh, Melissa Alsina, Nizar J. Bahlis, Frederic J. Reu, Nashat Y. Gabrail, Andrew Belch, Jeffrey V. Matous, Peter Lee, Peter Rosen, Michael Sebag, David H. Vesole, Lori A. Kunkel, Sandra M. Wear, Alvin F. Wong, Robert Z. Orlowski, David S. Siegel
Journal: Blood
Blood (2012) 119 (24): 5661–5670.
https://doi.org/10.1182/blood-2012-03-414359
Published: 2012
Journal Articles

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Ravi Vij, MD, Jonathan L. Kaufman, MD, Andrzej J Jakubowiak, MD, PhD, Michael Wang, MD, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Kevin T. McDonagh, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Andrew R Belch, MD, Frederic J. Reu, MD, Nashat Y. Gabrail, MD, Jeffrey Matous, MD, David H. Vesole, MD, PhD, Robert Z. Orlowski, MD, PhD, Sandra Wear, RN, Lori Kunkel, MD, Alvin F. Wong, PharmD, Peter Lee, MD, PhD, Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2011) 118 (21): 813.
https://doi.org/10.1182/blood.V118.21.813.813
Published: 2011
Journal Articles

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

Susan J Lee, Tina M Woo, Shirin Arastu-Kapur, PhD, Alvin F Wong, Pharm.D., Thomas E Renau, PhD, Christopher J Kirk, PhD
Journal: Blood
Blood (2011) 118 (21): 5068.
https://doi.org/10.1182/blood.V118.21.5068.5068
Published: 2011
Journal Articles

The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials,

Luhua Wang, MD, David S. Siegel, MD, PhD, Andrzej J Jakubowiak, MD, Alvin F. Wong, PharmD, Sandra Dixon, MS, Thomas E Renau, PhD, Ravi Vij, MD
Journal: Blood
Blood (2011) 118 (21): 3969.
https://doi.org/10.1182/blood.V118.21.3969.3969
Published: 2011
Journal Articles

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

Andrzej J Jakubowiak, MD, PhD, David S. Siegel, MD, PhD, Seema Singhal, MD, Thomas Martin, MD, Sagar Lonial, MD, Vishal Kukreti, MD, FRCPC, Nizar Bahlis, MD, Asher Alban Chanan-Khan, Melissa Alsina, MD, George Somlo, MD, Francis K Buadi, M.D., Frederic J. Reu, MD, Kevin W. Song, MD, Lori Kunkel, MD, Sandra M. Wear, RN, Alvin F. Wong, PharmD, Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MBA, MB, CHB, Sundar Jagannath, MD, Luhua Wang, MD
Journal: Blood
Blood (2011) 118 (21): 1875.
https://doi.org/10.1182/blood.V118.21.1875.1875
Published: 2011
Journal Articles

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

Seema Singhal, MD, David S. Siegel, MD, PhD, Thomas Martin, MD, Ravi Vij, MD, Luhua Wang, MD, Andrzej J Jakubowiak, MD, Sagar Lonial, MD, Vishal Kukreti, MD, FRCPC, Jeffrey A. Zonder, MD, Alvin F. Wong, PharmD, Leanne McCulloch, PharmD, Ashraf Z. Badros, MD, Ruben Niesvizky, MD, Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MBA, MB, CHB, Debbi Kotlovker, MS, Sundar Jagannath, MD
Journal: Blood
Blood (2011) 118 (21): 1876.
https://doi.org/10.1182/blood.V118.21.1876.1876
Published: 2011
Journal Articles

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

David Samuel diCapua Siegel, MD, PhD, Thomas Martin, MD, Michael Wang, MD, Ravi Vij, MBBS, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Sagar Lonial, MD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Melissa Alsina, MD, Asher A. Chanan-Khan, George Somlo, MD, Francis Buadi, MD, Frederic J. Reu, MD, Jeffrey A. Zonder, MD, Kevin Song, MD, Edward Stadtmauer, Alvin F. Wong, PharmD, Marcy Vallone, Yu-Lin Chang, Michael Kauffman, MD, PhD, Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MBChB, Seema B. Singhal, MD, The MMRC
Journal: Blood
Blood (2010) 116 (21): 985.
https://doi.org/10.1182/blood.V116.21.985.985
Published: 2010
Journal Articles

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Thomas Martin, MD, Seema B. Singhal, MD, Ravi Vij, MD, Michael Wang, MD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Melissa Alsina, MD, Asher A. Chanan-Khan, MD, George Somlo, MD, Francis Buadi, MD, Frederic J. Reu, MD, Jeffrey A. Zonder, MD, Kevin Song, MD, Edward A. Stadtmauer, MD, Alvin F. Wong, PharmD, Marcy Vallone, Yu-Lin Chang, Michael Kauffman, MD, PhD, Robert Z. Orlowski, MD, PhD, David Samuel diCapua Siegel, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3031.
https://doi.org/10.1182/blood.V116.21.3031.3031
Published: 2010
Journal Articles

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Sundar Jagannath, MD, Ravi Vij, MBBS, MD, Jonathan L. Kaufman, MD, Thomas Martin, MD, Ruben Niesvizky, MD, Nashat Y Gabrail, MD, Melissa Alsina, MD, Alvin F. Wong, PharmD, Mai H. Le, MD, Leanne McCulloch, PharmD, Alison L. Hannah, MD, Michael Kauffman, MD, PhD, David Samuel diCapua Siegel, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1953.
https://doi.org/10.1182/blood.V116.21.1953.1953
Published: 2010
Journal Articles

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Seema B. Singhal, MD, David Samuel diCapua Siegel, MD, PhD, Thomas Martin, MD, Ravi Vij, MBBS, MD, Michael Wang, MD, Andrzej J Jakubowiak, MD, PhD, Sagar Lonial, MD, Vishal Kukreti, MD, FRCPC, Jeffrey A. Zonder, MD, Alvin F. Wong, PharmD, Leanne McCulloch, Michael Kauffman, MD, PhD, Ashraf Z. Badros, MD, Ruben Niesvizky, MD, Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD
Journal: Blood
Blood (2010) 116 (21): 1954.
https://doi.org/10.1182/blood.V116.21.1954.1954
Published: 2010
Journal Articles

Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.

Richard R. Furman, MD, Nancy L. Bartlett, M.D., Alvin F. Wong, Pharm.D., Leanne M. McCulloch, Pharm.D., Gilbert N. Lam, Ph.D., Todd Rosenthal, Ian Flinn, M.D., John P. Leonard, M.D.
Journal: Blood
Blood (2006) 108 (11): 2429.
https://doi.org/10.1182/blood.V108.11.2429.2429
Published: 2006